Spots Global Cancer Trial Database for Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Official Title: A Phase II Study of Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Study ID: NCT03253068
Conditions
Interventions
Study Description
Brief Summary: To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus amurubicin (AMR).
Detailed Description: Open, uncontrolled, multi-center, phase II study.
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Wakayama Medical University, Wakayama, , Japan
Contact Details
Name: Hiroaki Akamatsu, M.D.
Affiliation: Third Department of Internal Medicine, Wakayama Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Nobuyuki Katakami, M.D., Ph.D.
Affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation
Role: PRINCIPAL_INVESTIGATOR
Name: Kazuhiko Nakagawa, M.D., Ph.D.
Affiliation: Department of Medical Oncology, Kinki University, Faculty of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
